Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.46 which represents a slight increase of $0.05 or 0.05% from the prior close of $92.41. The stock opened at $92 ...

A judge Monday denied a bid by a former Gilead Sciences Inc. COO to transfer to Ventura County a sexual harassment lawsuit filed against him by a former aide, ruling that the executive waived his ...

On the occasion of the 37th World AIDS Day, the Chinese Association of STD and AIDS Prevention and Control and China Youth ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...